Monday, September 24, 2018



Endo Agrees to Additional Stay of FDA Litigation Following FDA's Commitment to Use Best Efforts ...
In August 2018, an outsourcing facility announced it would commence bulk compounding of vasopressin and intervened in the litigation.
Endo once more agrees to delay FDA litigation
The lawsuit alleges the FDA's "interim policy" on compounding using bulk drug substances under Section 503 B of the Drug Quality and Security Act of ...


Post a Comment